CoreCap Advisors’s Jazz Pharmaceuticals JAZZ Stock Holding History

CoreCap Advisors’s Portfolio JAZZ Stock Details JAZZ Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$2.65K	Sell	11 -4	-27%	-$876	﹤0.01%	2466
2026 Q1	$2.84K	Hold	15	–	–	﹤0.01%	2327
2025 Q4	$2.55K	Buy	15 +8	+114%	+$1.23K	﹤0.01%	2408
2025 Q3	$923	Hold	7	–	–	﹤0.01%	2495
2025 Q2	$743	Hold	7	–	–	﹤0.01%	2461
2025 Q1	$869	Hold	7	–	–	﹤0.01%	2555
2024 Q4	$862	Hold	7	–	–	﹤0.01%	2399
2024 Q3	$780	Sell	7 -6	-46%	-$657	﹤0.01%	2301
2024 Q2	$1.39K	Sell	13 -2	-13%	-$220	﹤0.01%	1367
2024 Q1	$1.81K	Buy	+15	New	+$1.84K	﹤0.01%	2143
2022 Q4	$1.43K	Buy	+9	New	+$1.32K	﹤0.01%	2000
2022 Q3	–	Sell	-9	Closed	-$1K	–	1324
2022 Q2	$1K	Buy	+9	New	+$1.39K	﹤0.01%	2005
2022 Q1	–	Sell	-9	Closed	-$1K	–	1324
2021 Q4	$1K	Buy	+9	New	+$1.18K	﹤0.01%	2157

Other funds holding JAZZ

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

ACM

Argent Capital Management St Louis, Missouri $3.17B AUM 36.16% 1-Year Est. Return

WCM

Wedge Capital Management Charlotte, North Carolina $6.06B AUM 47.24% 1-Year Est. Return

Perpetual Ltd Sydney, New South Wales, Australia $7B AUM 19.75% 1-Year Est. Return

SAM

Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return

HWAM

Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return

BCM

BTC Capital Management Des Moines, Iowa $1.65B AUM 27.85% 1-Year Est. Return

AAP

Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return

Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return

CAMG

CWA Asset Management Group Naples, Florida $3.28B AUM 34.07% 1-Year Est. Return

CoreCap Advisors's JAZZ Position: Q2 2026 in Review

CoreCap Advisors reduced its Jazz Pharmaceuticals (JAZZ) stake by 27% in Q2 2026, selling an estimated $876 and leaving 11 shares worth $2.65K. The position accounts for ﹤0.01% of the portfolio, ranked #2466.

CoreCap Advisors first reported a position in JAZZ in Q4 2021 and has held it in 13 quarters since. The position peaked at $2.84K in Q1 2026. 69 funds tracked by Wall St. Rank hold JAZZ as of Q2 2026.

CoreCap Advisors held 11 shares of Jazz Pharmaceuticals worth $2.65K as of Q2 2026.
CoreCap Advisors sold 4 Jazz Pharmaceuticals shares in Q2 2026, an estimated $876.
Jazz Pharmaceuticals made up ﹤0.01% of CoreCap Advisors's portfolio in Q2 2026, its #2466 holding.
CoreCap Advisors first reported a position in Jazz Pharmaceuticals in Q4 2021 and has held it in 13 quarters since.
CoreCap Advisors's Jazz Pharmaceuticals position peaked at $2.84K in Q1 2026.
69 funds tracked by Wall St. Rank held Jazz Pharmaceuticals as of Q2 2026.

Based on CoreCap Advisors's 13F filing for Q2 2026, filed 6 Jul 2026.